Drug intelligence / Profile preview

thioguanine + carmustine + hydroxyurea

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This is a combination of three chemotherapy drugs with different mechanisms of action. Thioguanine is a purine antagonist that works by slowing or stopping the growth of cancer cells. Carmustine is an alkylating agent that damages DNA, preventing cell division. Hydroxyurea is an antimetabolite that interferes with DNA synthesis. This combination would likely be used for treating various cancers, particularly blood malignancies.

Other names: 6-thioguanine + BCNU + hydroxyurea

Targets

DNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on thioguanine + carmustine + hydroxyurea.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thioguanine + carmustine + hydroxyurea.

Explore the full profile